Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. develops intratumoral cancer therapies using proprietary non-covalent drug-conjugation technology. Its lead investigational product candidate, INT230-6, is designed for direct injection into tumors and combines cisplatin, vinblastine sulfate, and the SHAO diffusion and cell-penetration enhancer to disperse cytotoxic agents within cancer cells.
Recurring company news covers INT230-6 clinical development, including the INVINCIBLE-4 study in early-stage operable triple negative breast cancer and the INVINCIBLE-3 study in selected soft tissue sarcoma subtypes. Updates also address financial results, cash resources, intellectual-property protection for the intratumoral technology platform, at-the-market financing activity, Nasdaq listing compliance, and capital-structure actions affecting the company’s common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Intensity Therapeutics presented promising results from the INVINCIBLE study at the San Antonio Breast Cancer Symposium. In this Phase 2 trial, the drug INT230-6 achieved up to 100% tumor necrosis in patients with early-stage breast cancer, demonstrating significant immune response activation. The study involved 91 participants and highlighted INT230-6's potential as a pre-surgical treatment with manageable adverse effects. The data is bound to impact future cancer therapy approaches and reinforces the company's pioneering position in immune-based cancer treatments.
Intensity Therapeutics announced data from its ongoing Phase 1/2 study of INT230-6 presented at the CTOS Annual Meeting. Preliminary findings indicate that administering INT230-6 either alone or in combination with ipilimumab improves median overall survival (mOS) in patients with refractory sarcomas. Patients receiving a cumulative dose equivalent to 40% or more of their tumor burden exhibited an mOS of 715 days, compared to historical controls at 205 days. The results suggest favorable safety, supporting the potential of INT230-6 in treating metastatic sarcomas.
Intensity Therapeutics announced promising results from its phase 1/2 trial involving the cancer treatment INT230-6. Patients receiving INT230-6 alone had a median overall survival (mOS) of 373 days, significantly longer compared to historical data. In combination with pembrolizumab, the mOS was 205 days in a heavily pretreated patient group. The treatment has shown good tolerability and efficacy, inducing both tumor cell death and immune activation. Results will be presented at the SITC Annual Meeting, indicating ongoing research towards potential commercialization.
Intensity Therapeutics announced positive data from the INVINCIBLE study, showcasing significant tumor necrosis in early-stage breast cancers resistant to chemotherapy. The trial utilized INT230-6, which demonstrated up to 100% necrosis from a single injection, alongside increased immune cell activity in the tumor microenvironment. No surgical procedures were canceled or delayed due to the treatment. Results will be presented at the 2022 SITC Annual Meeting, indicating INT230-6's potential to alter treatment paradigms for patients awaiting surgery.